Trial Profile
A pivotal phase III study of ODACTRA™ in children with allergic asthma
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2017
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma
- Focus Registrational; Therapeutic Use
- Sponsors ALK-Abello
- 29 Aug 2017 New trial record
- 21 Aug 2017 According to an ALK media release, the company plans to initiate this study later in 2017 and will support approvals of ODACTRA for children with allergic asthma. The company is planning to initiate this trial in multiple locations including USA.